Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 17, 2024Journal of Cancer Research and Clinical OncologyOpen Access

Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHuilai LvHebei Medical UniversityFZFan ZhangHebei Medical UniversityCHChao HuangHebei Medical University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lv et al. (2024) studied this question.

synapsesocial.com/papers/68e69852b6db64358761e925https://doi.org/10.1007/s00432-024-05793-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial2022 · 61 citations
  2. 2Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma2023 · 12 citations
  3. 3Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma2021 · 847 citations
  4. 4Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma2023 · 22 citations